Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma

Shea, Lauren; Mehta‐Shah, Neha

doi:10.1007/s11899-020-00561-w

Cited by 29 publications

(29 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

Section: Discussionmentioning

confidence: 99%

“…Brentuximab vedotin is also a potential treatment for CTCL [218] . This monoclonal antibody has been shown to have efficacy against refractory cases of CTCL, as well as peripheral T-cell lymphoma [218] . During the studies performed using this medication, it was found that success is greatest in those CTCL cases where CD30 + positive cells are present.…”

Section: Discussionmentioning

confidence: 99%

“…During the studies performed using this medication, it was found that success is greatest in those CTCL cases where CD30 + positive cells are present. CD30 + falls within the TNF receptor class, which is involved in cell proliferation [218] . Thus, explaining the mechanism of this monoclonal antibody to inhibit specifically CD30 + expression [218] .…”

Section: Discussionmentioning

confidence: 99%

“…CD30 + falls within the TNF receptor class, which is involved in cell proliferation [218] . Thus, explaining the mechanism of this monoclonal antibody to inhibit specifically CD30 + expression [218] . Another monoclonal antibody used in the treatment of MF and SS is Alemtuzumab [219] .…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Overview of genetic signaling pathway interactions within cutaneous malignancies

Maner¹,

Dupuis²,

Su³

et al. 2020

JCMT

View full text Add to dashboard Cite

Melanoma and non-melanoma cutaneous malignancies are some of the leading causes of cancer-related death in the United States. Though melanoma is more known to have a high mortality rate, the total mortality per year is nearly equal for between melanoma and non-melanoma skin cancer. Moreover, the non-melanoma types of cutaneous malignancies have potential to become locally invasive and even metastasize with very little to no treatment options when advanced. The development of these malignancies involves various genetic pathways through the four hallmarks of cancer development: malignant cell growth, apoptosis evasion, the use of supporting stroma and vascularization, and modulating and promoting an inadequate immune response. The genetic signaling pathways of basal cell carcinoma, squamous cell carcinoma, verrucous carcinoma, basosquamous cell carcinoma, melanoma, and cutaneous T-cell lymphoma interact with each other through genetic predisposition as well as with environmental exposures. Furthermore, solar ultraviolet radiation and chronic inflammatory states are found to initiate the progression of many of these cutaneous malignancies. This paper includes validated models of genetic pathways, emerging pathways, and crosstalk between genetic pathways through the four hallmarks of cancer development. Moreover, unlike most reviews addressing oncogenetics of the well-recognized, as well as newly dynamic, interrelated, interactive, complex, and adaptive flux states.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Overview of genetic signaling pathway interactions within cutaneous malignancies

Maner¹,

Dupuis²,

Su³

et al. 2020

JCMT

View full text Add to dashboard Cite

show abstract

“…A prospective multicenter study found an ORR of pegylated liposomal doxorubicin for MF/SS of 56% (14/25), with five CR (20%), and a median PFS of 5 months [ 74 ]. Although CHOP is the standard regimen in patients with non-Hodgkin’s lymphoma including CTCL [ 75 ], the DOR is limited compared to surface molecular-targeted therapy such as brentuximab vedotin [ 76 ]. Overall, these cytotoxic drugs could be other options for the treatment of CTCL, although the incident ratio of SAEs was high (36–40%) [ 74 , 75 ].…”

Section: Systemic Treatment Options For Advanced Ctclsmentioning

confidence: 99%

Topical and Systemic Formulation Options for Cutaneous T Cell Lymphomas

et al. 2021

View full text Add to dashboard Cite

Although various anti-cutaneous T-cell lymphoma (CTCL) therapies are available for clinical use, appropriate chemotherapy lines for the treatment of CTCLs have yet to be established. Therefore, to date, various clinical trials for the treatment of advanced CTCLs are ongoing. In this review, we evaluate the therapeutic options that are available in clinical practice for treatment of early- and advanced-stage CTCLs (targeted therapies, histone deacetylase (HDAC) inhibitors, retinoids, interferons, cytotoxic drugs, etc.). We also examine clinical trials of novel regimens for the treatment of CTCLs.

show abstract

The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively

Guo

et al. 2021

Cancer Medicine

View full text Add to dashboard Cite

show abstract

Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma

Cited by 29 publications

References 51 publications

Overview of genetic signaling pathway interactions within cutaneous malignancies

Overview of genetic signaling pathway interactions within cutaneous malignancies

Topical and Systemic Formulation Options for Cutaneous T Cell Lymphomas

The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively

Contact Info

Product

Resources

About